Cantargia AB (publ)

SSE:CANTA.ST

3.32 (SEK) • At close February 20, 2024
Bedrijfsnaam Cantargia AB (publ)
Symbool CANTA.ST
Munteenheid SEK
Prijs 3.32
Beurswaarde 554,400,160
Dividendpercentage 0%
52-weken bereik 3.202 - 8.195
Industrie Biotechnology
Sector Healthcare
CEO Mr. Goran Forsberg
Website https://www.cantargia.com

An error occurred while fetching data.

Over Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the

Vergelijkbare Aandelen

C-Rad AB (publ) logo

C-Rad AB (publ)

CRAD-B.ST

46.55 SEK

Diamyd Medical AB (publ) logo

Diamyd Medical AB (publ)

DMYD-B.ST

13.3 SEK

Senzime AB (publ) logo

Senzime AB (publ)

SEZI.ST

7.25 SEK

Isofol Medical AB (publ) logo

Isofol Medical AB (publ)

ISOFOL.ST

0.616 SEK

Xspray Pharma AB (publ) logo

Xspray Pharma AB (publ)

XSPRAY.ST

44 SEK

ADDvise Group AB (publ) logo

ADDvise Group AB (publ)

ADDV-A.ST

11.6 SEK

Biovica International AB (publ) logo

Biovica International AB (publ)

BIOVIC-B.ST

2.34 SEK

Paxman AB (publ) logo

Paxman AB (publ)

PAX.ST

38.6 SEK

Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

XBRANE.ST

2.085 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)